NDA 020757 · Sanofi Aventis US
Avapro
Irbesartan · Oral · Angiotensin 2 Receptor Blocker
NovelLast checked: Nov 19, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 30, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
128
38 Phase 3, 4 recruiting
FAERS reports
45,095
35,266 serious, 3,341 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue AVAPRO as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue AVAPRO as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )
What it is approved for
From the label in effect Aug 24, 2026.
AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension AVAPRO ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in...
Mechanism: Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT 1 angiotensin II receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 17, 2002 Supplement 21 · Efficacy · priority review ReviewLetterLabel
- May 26, 2001 Supplement 14 · Efficacy Review
- Sep 30, 1997 Original approval · Type 1 - New Molecular Entity ReviewOther Important Information from FDAPediatric Statistical Review
3 products under this application
- AVAPRO · IRBESARTAN 300MG · TABLET, ORAL · Prescription · TE AB
- AVAPRO · IRBESARTAN 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
- AVAPRO · IRBESARTAN 150MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Irbesartan" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00249795 · 9,016 participants · Start Jun 2003 · Primary completion Aug 2009
Drug: Irbesartan; placebo · For: Atrial Fibrillation; Cardiovascular Disease
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 30 sites in all
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00249873 · 7,554 participants · Start Jun 2003 · Primary completion Mar 2009
Drug: clopidogrel (SR25990C); placebo · For: Atrial Fibrillation; Vascular Risk
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 30 sites in all
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)Pivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00243178 · 6,706 participants · Start Jul 2003 · Primary completion Sep 2005
Drug: clopidogrel (SR25990C) · For: Atrial Fibrillation; Vascular Risk
Sites: Bridgewater, New Jersey; Macquarie Park, Australia; Vienna, Austria · 32 sites in all
- Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)Pivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00095238 · 4,128 participants · Start Jun 2002 · Primary completion Jul 2008
Drug: Irbesartan; Placebo · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Peoria, Arizona; Tucson, Arizona · 229 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic PatientsPivotal-lookingRecruiting
Martin HuelsmannAcademic, hospital or other
NCT02817360 · 2,400 participants (planned) · Start Feb 2016 · Primary completion Dec 2025
Drug: RAS-antagonist and beta-blocker up-to maximal dosages · For: Heart Diseases; Diabetes Mellitus, Type 2
Sites: Mödling, Austria; Graz, Austria; Linz, Austria · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,569
- nausea2,514
- diarrhoea2,369
- drug ineffective2,237
- acute kidney injury2,187
- dizziness2,059
- dyspnoea2,058
- fall2,038
- headache1,966
- off label use1,773
- asthenia1,767
- malaise1,700
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 834 |
| 2005 | 1,000 |
| 2006 | 1,052 |
| 2007 | 1,194 |
| 2008 | 1,227 |
| 2009 | 1,312 |
| 2010 | 1,329 |
| 2011 | 1,484 |
| 2012 | 1,514 |
| 2013 | 1,209 |
| 2014 | 1,486 |
| 2015 | 1,794 |
| 2016 | 1,991 |
| 2017 | 1,947 |
| 2018 | 2,715 |
| 2019 | 3,633 |
| 2020 | 3,369 |
| 2021 | 2,778 |
| 2022 | 2,931 |
| 2023 | 2,893 |
| 2024 | 2,637 |
| 2025 | 2,763 |
| 2026 | 2,001 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Avapro (Irbesartan)
2024 spending
$2.3M
Beneficiaries
992
3,829 claims
Per beneficiary
$2,316
$8.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,644,111 |
| 2021 | $4,168,422 |
| 2022 | $3,447,668 |
| 2023 | $3,264,701 |
| 2024 | $2,297,411 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.
Zhang Z, Yang H, Guo H · Int J Clin Pharm 2024 · Comparative Study, Review
- Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Desai AS, Webb DJ, Taubel J, et al. · N Engl J Med 2023 · Clinical Trial, Phase I, Randomized Controlled Trial
- Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM, Sinha A, Cooper TE · Cochrane Database Syst Rev 2022 · Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.